Both newborns and elderly adults suffer from physiological immunodeficiency. The molecular mechanisms responsible for this immunodeficiency are currently investigated by many laboratories. The aim of our investigations was to answer the question wether these immunodeficiencies could be influenced by bovine and/or human diacetyl-splenopentin, two newly developed immunostimulatory peptides. The in vitro effects of these peptides were studied using the lymphocyte transformation test and the detection of the immunoglobulin production (IgG, IgM) by lymphocytes. Thymopentin was used as standard for these investigations. The age dependence of lymphocyte sensitivity was estimated using cells of the following groups of blood donors: newborns (cord blood); young donors (20-30 yr); old donors (over 70 yr). All peptides were shown to have the same effects. The stimulated lymphocyte proliferation (PHA, anti-CD3) was inhibited in young donors and further increased in old donors. There was no influence in the case of newborns. The biological activity of human diacetyl-splenopentin was shown to be higher in comparison with bovine diacetyl-splenopentin.
Download full-text PDF |
Source |
---|
Pharmazie
January 1992
Institut für Klinische Immunologie, Friedrich-Schiller-Universität Jena.
The influence of Berlopentin on caffeine clearance was measured after a 6 week i.v. treatment or a 4 week s.
View Article and Find Full Text PDFPharmazie
December 1990
Institut für Klinische Immunologie, Friedrich-Schiller-Universität Jena.
More and more new immunostimulatory substances are developed. Besides old and new drugs have to be examined with regard to their side effects. Hence it follows demands for effective test possibilities.
View Article and Find Full Text PDFExp Clin Endocrinol
December 1990
Institute of Clinical Immunology, Friedrich Schiller University Jena/GDR.
We investigated the effect of BCH 069 (similar structure as thymopentin) on concentrations of hormones of the hypophysis, adrenals, gonads and thyroid glands in men after a therapy period of 4 or 6 weeks. No significant effects of BCH 069 three times weekly 50 mg s.c.
View Article and Find Full Text PDFAllergol Immunopathol (Madr)
January 1991
Institut für Immunologie, Medical School, Friedrich Schiller University, Jena, G.D.R.
Diacetyl-splenopentin (BCH 069) is a new pentapeptide of splenin modified by twofold acetylation. BCH 069 has thymopentin-like activity demonstrated by in vivo animal and in vitro human studies. Two groups of patients received 50 mg BCH 069 and placebo, respectively, by subcutaneous injection 3 times weekly for 4 weeks.
View Article and Find Full Text PDFAllerg Immunol (Leipz)
July 1991
Institut für Klinische Immunologie, Friedrich-Schiller-Universität Jena.
Both newborns and elderly adults suffer from physiological immunodeficiency. The molecular mechanisms responsible for this immunodeficiency are currently investigated by many laboratories. The aim of our investigations was to answer the question wether these immunodeficiencies could be influenced by bovine and/or human diacetyl-splenopentin, two newly developed immunostimulatory peptides.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!